Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 220.1 Million USD | 17.04% |
| 2022 | 188.06 Million USD | 10.84% |
| 2021 | 169.67 Million EUR | -16.44% |
| 2020 | 203.05 Million EUR | 22.76% |
| 2019 | 165.41 Million EUR | 28.02% |
| 2018 | 129.2 Million EUR | 39.55% |
| 2017 | 92.58 Million EUR | 686.73% |
| 2016 | 11.76 Million EUR | 78.57% |
| 2015 | 6.59 Million EUR | -69.48% |
| 2014 | 21.59 Million EUR | 172.83% |
| 2013 | 7.91 Million EUR | -5.69% |
| 2012 | 8.39 Million EUR | 1319.46% |
| 2011 | -688.22 Thousand EUR | -207.58% |
| 2010 | 639.71 Thousand EUR | 33.28% |
| 2009 | 479.97 Thousand USD | -48.08% |
| 2008 | 924.35 Thousand EUR | 102.57% |
| 2007 | -35.89 Million EUR | -50.83% |
| 2006 | -23.79 Million USD | -317.94% |
| 2005 | -5.69 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 68.95 Million USD | 3.44% |
| 2024 Q2 | 65.76 Million USD | 40.16% |
| 2024 Q1 | 46.92 Million USD | -31.29% |
| 2023 FY | 220.1 Million USD | 17.04% |
| 2023 Q4 | 68.29 Million USD | 17.02% |
| 2023 Q1 | 38.46 Million USD | -20.44% |
| 2023 Q2 | 49.17 Million USD | 27.83% |
| 2023 Q3 | 58.36 Million USD | 18.7% |
| 2022 Q1 | 41.74 Million USD | 22.07% |
| 2022 Q2 | 46.11 Million USD | 10.49% |
| 2022 Q3 | 51.85 Million USD | 12.44% |
| 2022 Q4 | 48.34 Million USD | -6.77% |
| 2022 FY | 188.06 Million USD | 10.84% |
| 2021 Q3 | 46.02 Million EUR | 3.91% |
| 2021 Q2 | 44.29 Million EUR | 17.23% |
| 2021 Q1 | 37.78 Million EUR | -39.2% |
| 2021 Q4 | 34.19 Million EUR | -25.71% |
| 2021 FY | 169.67 Million EUR | -16.44% |
| 2020 FY | 203.05 Million EUR | 22.76% |
| 2020 Q4 | 62.14 Million EUR | 18.69% |
| 2020 Q1 | 48.42 Million EUR | 0.35% |
| 2020 Q2 | 40.12 Million EUR | -17.13% |
| 2020 Q3 | 52.35 Million EUR | 30.48% |
| 2019 Q2 | 42.68 Million EUR | 27.53% |
| 2019 FY | 165.41 Million EUR | 28.02% |
| 2019 Q4 | 48.25 Million EUR | 17.69% |
| 2019 Q3 | 41 Million EUR | -3.94% |
| 2019 Q1 | 33.46 Million EUR | 0.17% |
| 2018 Q4 | 33.41 Million EUR | -12.07% |
| 2018 Q2 | 27.63 Million EUR | -8.38% |
| 2018 FY | 129.2 Million EUR | 39.55% |
| 2018 Q3 | 38 Million EUR | 37.54% |
| 2018 Q1 | 30.15 Million EUR | -14.51% |
| 2017 Q2 | 16.16 Million EUR | 9.91% |
| 2017 Q1 | 14.7 Million EUR | 160.58% |
| 2017 Q3 | 26.43 Million EUR | 63.54% |
| 2017 FY | 92.58 Million EUR | 686.73% |
| 2017 Q4 | 35.27 Million EUR | 33.44% |
| 2016 Q1 | 1.76 Million EUR | 41.91% |
| 2016 FY | 11.76 Million EUR | 78.57% |
| 2016 Q4 | 5.64 Million EUR | 126.95% |
| 2016 Q3 | 2.48 Million EUR | 32.8% |
| 2016 Q2 | 1.87 Million EUR | 6.13% |
| 2015 Q1 | 842.51 Thousand EUR | -95.81% |
| 2015 FY | 6.59 Million EUR | -69.48% |
| 2015 Q4 | 1.24 Million EUR | -41.13% |
| 2015 Q3 | 2.11 Million EUR | -11.7% |
| 2015 Q2 | 2.39 Million EUR | 183.94% |
| 2014 Q3 | 489.09 Thousand EUR | -33.04% |
| 2014 Q4 | 20.09 Million EUR | 4009.18% |
| 2014 FY | 21.59 Million EUR | 172.83% |
| 2014 Q1 | 277.81 Thousand EUR | -35.19% |
| 2014 Q2 | 730.39 Thousand EUR | 162.91% |
| 2013 Q3 | 1.1 Million EUR | -80.82% |
| 2013 Q4 | 428.68 Thousand EUR | -61.21% |
| 2013 FY | 7.91 Million EUR | -5.69% |
| 2013 Q1 | 619.81 Thousand EUR | -93.56% |
| 2013 Q2 | 5.76 Million EUR | 829.57% |
| 2012 Q2 | -2.24 Million EUR | -448.04% |
| 2012 Q3 | 367.55 Thousand EUR | 116.36% |
| 2012 FY | 8.39 Million EUR | 1319.46% |
| 2012 Q4 | 9.62 Million EUR | 2519.08% |
| 2012 Q1 | 645.65 Thousand EUR | 139.36% |
| 2011 Q2 | -415.8 Thousand EUR | -156.96% |
| 2011 Q1 | 729.95 Thousand EUR | 583.38% |
| 2011 Q3 | 637.93 Thousand EUR | 253.42% |
| 2011 Q4 | -1.64 Million EUR | -357.13% |
| 2011 FY | -688.22 Thousand EUR | -207.58% |
| 2010 Q4 | -151.01 Thousand EUR | -141.81% |
| 2010 Q3 | 361.14 Thousand EUR | 67.51% |
| 2010 Q2 | 215.59 Thousand EUR | 0.0% |
| 2010 FY | 639.71 Thousand EUR | 33.28% |
| 2010 Q1 | - USD | -100.0% |
| 2009 FY | 479.97 Thousand USD | -48.08% |
| 2009 Q4 | 792.72 Thousand EUR | 195.82% |
| 2009 Q3 | 267.97 Thousand EUR | -23.49% |
| 2009 Q1 | 137.97 Thousand EUR | 0.0% |
| 2009 Q2 | 350.26 Thousand EUR | 153.86% |
| 2008 FY | 924.35 Thousand EUR | 102.57% |
| 2007 FY | -35.89 Million EUR | -50.83% |
| 2006 FY | -23.79 Million USD | -317.94% |
| 2005 FY | -5.69 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 9024454.244% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1780.267% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 68988.632% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -84.794% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 953.182% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 456189.02% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 177244.651% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -1367.458% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -7095451.257% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -2147.335% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -334770.983% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 644621.23% |
| Mesoblast Limited | -35.16 Million USD | 725.864% |
| Marizyme, Inc. | 457.7 Thousand USD | -47988.931% |
| Genus plc | 178.7 Million USD | -23.17% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -353617.096% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -53562.307% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 2001045.455% |
| ContraFect Corporation | -154 Thousand USD | 143024.675% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 440308.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -286639.36% |
| IMV Inc. | -962.29 Thousand USD | 22972.748% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 56900.886% |
| MultiCell Technologies, Inc. | 49.32 USD | -446277272.263% |
| ONE Bio Corp. | 20.12 Million USD | -993.661% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -446.639% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -450010.429% |
| Q BioMed Inc. | -8988.00 USD | 2448965.154% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -678.991% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 1427122.822% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -396.201% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 19380.781% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -314334.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 4444849.596% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -156557.651% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 225812.967% |
| GB Sciences, Inc. | -624.00 USD | 35273176.923% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 255951.583% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 97.089% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 105819330.769% |
| Enzolytics Inc. | 30.7 Thousand USD | -716664.361% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -45523.745% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 80.144% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 42879.343% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -35551.07% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 46.258% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 2485465.854% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 262600.447% |
| Kadimastem Ltd | -630.13 Thousand USD | 35029.492% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -22178.161% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -2190.126% |
| BioStem Technologies, Inc. | 15.42 Million USD | -1326.944% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1859871.863% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -124562.438% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -124562.438% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -16118.188% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 759079.31% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -48807.327% |
| SYBLEU INC | 11.69 Thousand USD | -1881774.145% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -4676.563% |
| Bioxytran, Inc. | -8285.00 USD | 2656756.608% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 59109.115% |
| Neutra Corp. | 14.33 Thousand USD | -1535330.764% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 268519.512% |
| PureTech Health plc | -1.6 Million USD | 13830.755% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 22083.229% |
| IXICO plc | 3.27 Million USD | -6631.009% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 31815.274% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 12389.447% |
| CSL Limited | 7.7 Billion USD | 97.143% |
| Cellectis S.A. | 18 Thousand USD | -1222700.0% |